Indian Pharmas Threaten Production Halt If Price Increases Barred
This article was originally published in PharmAsia News
Indian pharmaceuticals are threatening to stop making certain drugs if the government does not allow price increases. B.N. Singh, president of the Indian Drug Manufacturers' Association, said his group has appealed to the Ministry of Chemicals and Fertilisers to be allowed to raise prices to reflect the higher cost of bulk drugs and packaging materials. The IDMA also says Indian drug makers face increased costs of freight and accommodation and can no longer absorb them. The group cites the recent substantial increase in the cost of bulk drugs imported from China. (Click here for more
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.